Overview of the Market
Social awareness and interest in autism has increased rapidly. The most recent data suggest that one in 110 children have an autism spectrum disorder (ASD).[101] Owing to an increase in the diagnosis of these disorders and an increase in public awareness, research surrounding the treatment of target symptoms of PDDs has also increased. The American Academy of Child and Adolescent Psychiatry (AACAP) has developed general guidelines for treating individuals with PDDs.[8] However, there are only two medications that have received FDA approval for use in this population. This is challenging, as pharmacotherapy is often the rule and not the exception in this population. As described previously, atypical antipsychotics are commonly used in this population to treat irritability. Currently, the only two FDA-approved medications to treat irritability in autistic individuals are risperidone and aripiprazole.
Pediatr Health. 2010;4(4):375-381. © 2010 Future Medicine Ltd.
Comments